Dyadic reports second quarter 2021 financial results and highlights recent company progress

Executed binding term sheet with sorrento therapeutics (nasdaq:srne) to outlicense c1 protein production platform for the development and commercialization of vaccines, therapeutic antibodies, protein therapeutics, and diagnostics for coronaviruses, including dyai-100, dyadic's lead covid-19 vaccine candidate new collaboration with india's syngene international to develop a covid-19 vaccine candidate new co-development collaboration with south africa's rubic consortium to establish a basis for researching, developing, and manufacturing multiple other c1 produced vaccines in addition to dyai-100 potential to support vaccine production for up to 100% of the world's population dyadic's c1 production platform utilized in zapi study published in "vaccines," a leading peer-reviewed scientific journal sale of equity interests in bdi holdings and vlp bio realizing 1.3 million euros in cash and approximately 30% roi 66.5% year over year revenue increase cash and investment grade securities of $25.8 million as of june 30, 2021 jupiter, fl / accesswire / august 12, 2021 / dyadic international, inc. ("dyadic", "we", "us", "our", or the "company") (nasdaq:dyai), a global biotechnology company focused on further improving, applying, and deploying its proprietary c1-cell protein production platform to accelerate development, lower production costs and improve the performance of biologic vaccines and therapeutics today announced its financial results for the second quarter of 2021 and highlighted recent company progress. "since the sale of dyadic's industrial biotech business to dupont, we have focused our efforts on using synthetic biology to reengineer our versatile industrially proven c1 protein production platform to address biologic vaccine and drug production for the animal and human health markets.
DYAI Ratings Summary
DYAI Quant Ranking